Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study

The tirzepatide group experienced an incidence rate of 1.9 per 100 person-years for the composite outcome, significantly lower than the 3.5 per 100 person-years observed in the bariatric metabolic surgery group.

• Tirzepatide is associated with a lower risk of major adverse health events compared to bariatric metabolic surgery.
• The incidence of all-cause mortality was significantly reduced in the tirzepatide group at 0.4 per 100 person-years versus 0.9 in the BMS group.
• Major adverse kidney events occurred less frequently in the tirzepatide group, with rates of 0.7 compared to 1.8 per 100 person-years in the BMS group.
• Major adverse liver outcomes were also lower in the tirzepatide group, with an incidence of 0.8 versus 2.0 per 100 person-years in the BMS group.
• These findings suggest tirzepatide could be a safer, less invasive treatment option for adults with metabolic-associated steatotic liver disease and obesity.

AI simplified